Trenton Overall, DO
Neurology · St George, UTNPI 1841575032
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $6,408 of the $7,787 with a category attached, or 82.3%. It is spread thinly across 35 manufacturers, the largest accounting for just 20.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $2,502 and has fallen 86.8% since, to $331 in 2024.
Across 387 payments — averaging $20.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$2K
- Bioventus LLC$1K
- AbbVie$975
- Biogen$884
- EMD Serono, Inc.$421
- Novartis$312
- plus $2K from 29 others
What the payments were for
- Travel & lodging$1,36718%
- Food & beverage$6,40882%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 70 | $1,566 |
| Bioventus LLC | 3 | $1,216 |
| AbbVie(2 entities) | 79 | $975 |
| Biogen | 55 | $884 |
| EMD Serono, Inc. | 25 | $421 |
| Novartis | 17 | $312 |
| Amgen(2 entities) | 16 | $256 |
| SK Life Science, Inc. | 12 | $237 |
| Lundbeck LLC | 9 | $220 |
| Biohaven Pharmaceuticals, Inc. | 14 | $185 |
| Eisai Inc. | 15 | $185 |
| Teva Pharmaceuticals USA, Inc. | 8 | $181 |
| Genentech USA, Inc. | 6 | $121 |
| Jazz Pharmaceuticals Inc. | 4 | $106 |
| Argenx US, Inc. | 4 | $94 |
| Livanova USA, Inc. | 6 | $91 |
| Bristol Myers Squibb | 5 | $87 |
| Acadia Pharmaceuticals Inc | 4 | $69 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $68 |
| Lilly USA, LLC | 5 | $64 |
| Pfizer | 3 | $59 |
| Sanofi-aventis U.S. LLC | 3 | $56 |
| Abbott | 3 | $44 |
| Upsher-smith Laboratories LLC | 3 | $38 |
| UCB, Inc. | 2 | $36 |
| AstraZeneca | 2 | $35 |
| ANI Pharmaceuticals, Inc. | 2 | $30 |
| Boston Scientific | 1 | $25 |
| Sanofi | 1 | $23 |
| Otto Bock Healthcare LP | 1 | $23 |
| Inspire Medical Systems, Inc. | 1 | $22 |
| CSL Behring | 1 | $16 |
| Neurocrine Biosciences, Inc. | 1 | $15 |
| Catalyst Pharmaceuticals, Inc. | 1 | $14 |
| Impel Pharmaceuticals Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Stimrouter Implantable Kit$1,186
- ACTIVA$180
How this compares
$7,787 in reported general payments places this provider in the 70th percentile of 157 neurology providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 18 | $96,333 |
| NuplazidPimavanserin Tartrate | 16 | $91,888 |
| CopaxoneGlatiramer Acetate | 13 | $73,693 |
| EpidiolexCannabidiol (Cbd) | 20 | $32,530 |
| NuedextaDextromethorphan Hbr/Quinidine | 11 | $17,109 |
| NeuproRotigotine | 13 | $13,260 |
| Emgality SyringeGalcanezumab-Gnlm | 11 | $7,303 |
| XareltoRivaroxaban | 12 | $6,472 |
| MyrbetriqMirabegron | 12 | $6,152 |
| Pyridostigmine Bromide | 36 | $4,977 |
| DilantinPhenytoin Sodium Extended | 11 | $4,935 |
| Lamotrigine ErLamotrigine | 12 | $4,833 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 77 | $4,214 |
| Lacosamide | 39 | $2,717 |
| Gabapentin | 69 | $2,400 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Acadia Pharmaceuticals IncNuplazid | $69 | $91,88816 claims |
| Teva Pharmaceuticals USA, Inc.Copaxone | $181 | $73,69313 claims |
| UCB, Inc.Neupro | $36 | $13,26013 claims |
| PfizerDilantin | $59 | $4,93511 claims |
| Upsher-smith Laboratories LLCTopiramate | $38 | $32726 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 157 neurology providers in Utah.
Other neurology in St George
- Robert YapundichSt George$107K
- Shawn AllenSt George$36K
- Timothy WestSalt Lake City$856K
- Richard HammondOgden$707K
- Jeffrey GrovesDraper$628K
- Stacey SteevesSalt Lake City$548K
- Amir ArainSalt Lake City$329K
- Mark BrombergSalt Lake City$265K
- April ErwinSalt Lake City$263K
- Yashma PatelLehi$251K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.